National Network Genomic Medicine Lung Cancer, Germany

Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05934032

Acronym

nNGM

Enrollment

30000

Registered

2023-07-06

Start date

2018-04-01

Completion date

2030-12-31

Last updated

2023-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

carcinoma, non-small-cell lung* / diagnosis, carcinoma, non-small-cell lung* / genetics, precision medicine, lung neoplasms, neoplasms by site, registry, pathology, molecular

Brief summary

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

Detailed description

Within the national Network Genomic Medicine Lung Cancer (nNGM), comprehensive molecular diagnostics and treatment recommendations are provided by 23 certified cancer centres according to standardized procedures for patients with non-resectable NSCLC. More than 400 network partners across Germany (including hospitals and oncological practices) report data on subsequent treatment and outcomes to the nNGM registry. Clinical outcomes are continuously evaluated through analysis of data collected in a decentralized registry. The nNGM registry records the patient journey and course of the disease from first histologically confirmed diagnosis to death or loss to follow-up and comprises detailed data on demographic and clinical characteristics, molecular diagnostics (including comprehensive biomarker testing results), treatments (targeted therapy, immunotherapy, chemotherapy, radiotherapy, best supportive care) and outcomes (overall survival, response, disease progression, time to next treatment). Patients have been actively involved throughout all stages of the design and running of the network and its registry.

Interventions

OTHERobservational, non-interventional

observational, non-interventional

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \[UICC\] stage IIIb/IV; non-resectable NSCLC) * From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)

Exclusion criteria

* Missing written informed consent

Design outcomes

Primary

Measure	Time frame	Description
molecular testing	1 year	descriptive data on results, frequency and methods of molecular testing
treatment patterns	from first diagnosis to death or loss to follow-up, whichever came first, assessed up to 100 months	descriptive data on systemic treatments (including combination and sequence of treatments)
overall survival	assessed up to 100 months	overall survival (in months)
time to next treatment	from start of treatment to the start of the next therapy, death or loss to follow-up, whichever came first, assessed up to 100 months	time to next treatment (in months)
progression free survival	from start of treatment to tumour progression, death or loss to follow-up, whichever came first, assessed up to 100 months	progression free survival (in months)

Countries

Germany

Contacts

Primary ContactAnna Rasokat

anna.rasokat@uk-koeln.de004922147896992

Backup ContactnNGM Geschäftsstelle

NNGM-Geschaeftsstelle@uk-koeln.de004922147896991

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026